Long-term outcomes of mesenchymal stem cell therapy in severe COVID-19 patients: 3-year follow-up of a randomized, double-blind, placebo-controlled trial.

ABSTRACT:

Background

The long-term effects and outcomes of human mesenchymal stem cell (MSC) therapy in patients with severe coronavirus disease 2019 (COVID-19) remain poorly understood. This study aimed to evaluate the extended safety and efficacy of MSC treatment in severe patients with COVID-19 who participated in our earlier randomized, double-blind, placebo-controlled clinical trial, with follow-up conducted over 3 years.

Methods

One hundred patients with severe COVID-19 were randomized to receive either an MSC infusion (n = 65, 4 × 10⁷ cells/dose, on days 0, 3, and 6) or a placebo, with both groups receiving the standard of care. At 36 months post-MSC therapy, patients were followed up to long-term safety and efficacy, particularly the effects of MSC therapy on persis

SUBMITTER: Yuan MQ 

PROVIDER: S-EPMC11863646 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature